|
Effect of activating chimeric receptor on IL-15 armored NK cell on providing in vitro and in vivo antigen specific tumor response. |
|
|
Employment - American Academic Health System; Chartercare; Tenet Healthcare |
Research Funding - Nkarta; Takeda; TriSalus Life Sciences |
Travel, Accommodations, Expenses - TriSalus Life Sciences |
|
|
|
Research Funding - Nkarta; Takeda; TNK Therapeutics; TriSalus Life Sciences |
Patents, Royalties, Other Intellectual Property - Chartercare |
|
|
|
Research Funding - Nkarta |
|
|
|
Research Funding - Nkarta |
|
|
|
Research Funding - Nkarta |
|
|
|
Research Funding - TriSalus Life Sciences |
|
|
|
Stock and Other Ownership Interests - Arcus Biosciences |
Patents, Royalties, Other Intellectual Property - Arcus Biosciences; ChemoCentryx |
|
|
|
|
Stock and Other Ownership Interests - Nkarta |
Patents, Royalties, Other Intellectual Property - Nkarta |
|
|
|
Stock and Other Ownership Interests - Instatin |
Research Funding - Nkarta; Takeda; TriSalus Life Sciences |
Patents, Royalties, Other Intellectual Property - BIDMC/UC Davis |
|
|
No Relationships to Disclose |